Neogenomics (NEO) Change in Accured Expenses (2010 - 2026)

Neogenomics has reported Change in Accured Expenses for 17 years, with the latest figure at $718000.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 103.13% year-over-year to $718000.0; the trailing twelve-month figure through Mar 2026 stood at $19.0 million (up 170.79% YoY), and the FY2025 full-year result was -$4.7 million, down 17.22% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $718000.0, down from $6.9 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $30.7 million in Q2 2025, with the low at -$23.0 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged -$628411.8 across 5 years, with a median of -$138000.0 in 2024.
• The largest YoY upside for Change in Accured Expenses was 1531.4% in 2025 against a maximum downside of 16535.51% in 2025.
• Neogenomics' Change in Accured Expenses stood at $1.8 million in 2022, then sank by 184.21% to -$1.6 million in 2023, then sank by 93.0% to -$3.0 million in 2024, then jumped by 328.85% to $6.9 million in 2025, then sank by 89.56% to $718000.0 in 2026.
• The last three Change in Accured Expenses figures came in at $718000.0 (Q1 2026), $6.9 million (Q4 2025), and -$19.3 million (Q3 2025), per Business Quant data.